Department of Research and Development, IMG Pharma Biotech S.L., 48160 Derio, Spain.
Experimental Ophthalmo-Biology Group (GOBE), Department of Cell Biology and Histology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
Int J Mol Sci. 2022 May 18;23(10):5639. doi: 10.3390/ijms23105639.
Matrix metalloproteinases are a family of enzymes fundamental in inflammatory processes. Between them, MMP-9 is up-regulated during inflammation; thus, its quantification in non-invasive fluids is a promising approach for inflammation identification. To this goal, a biomarker quantification test was developed for ocular inflammation detection using anti-MMP-9 antibody microarrays (AbMAs). After validation with eight healthy control tear samples characterized by ELISA, 20 samples were tested from individuals diagnosed with ocular inflammation due to: cataracts, glaucoma, meibomian gland dysfunction, allergy, or dry eye. Concentration values of tear MMP-9 were obtained for each sample, and 12 patients surpassed the pathological threshold (30 ng/mL). A significant elevation of MMP-9 concentration in the tears of glaucoma patients compared with healthy controls was observed. In order to evaluate the diagnostic ability, an ROC curve analysis was performed using our data, determining the optimal threshold for the test at 33.6 ng/mL of tear MMP-9. In addition, a confusion matrix was applied, estimating sensitivity at 60%, specificity at 88%, and accuracy at 68%. In conclusion, we demonstrated that the AbMAs system allows the quantification of MMP-9 in pathologies that involve inflammation of the ocular surface.
基质金属蛋白酶是一组在炎症过程中起基础作用的酶。其中,MMP-9 在炎症期间上调;因此,在非侵入性流体中对其进行定量是识别炎症的一种很有前途的方法。为此,使用抗 MMP-9 抗体微阵列(AbMAs)开发了一种用于眼部炎症检测的生物标志物定量测试。在用 ELISA 对 8 个健康对照眼泪样本进行验证后,对 20 个因白内障、青光眼、睑板腺功能障碍、过敏或干眼症而被诊断为眼部炎症的个体进行了测试。为每个样本获得了眼泪 MMP-9 的浓度值,并且 12 名患者超过了病理阈值(30ng/mL)。与健康对照组相比,青光眼患者眼泪中 MMP-9 浓度明显升高。为了评估诊断能力,使用我们的数据进行了 ROC 曲线分析,确定测试的最佳阈值为 33.6ng/mL 的眼泪 MMP-9。此外,还应用了混淆矩阵,估计敏感性为 60%,特异性为 88%,准确性为 68%。总之,我们证明了 AbMAs 系统允许定量检测涉及眼表面炎症的病理中的 MMP-9。